Bleomycin: female-specific dominant lethal effects in mice

P D Sudman1, J C Rutledge, J B Bishop

  • 1Biology Division, Oak Ridge National Laboratory, TN 37831-8077, USA.

Mutation Research
|December 1, 1992
PubMed

Insights

Bleomycin, an antitumor antibiotic, induces dominant lethal mutations in female mice but not males. This gender-specific genetic risk highlights potential differences in cancer chemotherapy safety.

Area of Science:

  • Toxicology
  • Genetics
  • Pharmacology

Background:

  • Chemical mutagens exhibit variable efficacy in inducing dominant lethal mutations between male and female mice.
  • Adriamycin is a known female-specific mutagen, prompting investigation into other antitumor antibiotics.
  • Understanding gender-specific genetic risks from chemotherapy is crucial.

Purpose of the Study:

  • To evaluate the potential of bleomycin to induce dominant lethal mutations in male and female mice.
  • To investigate the gender-specific effects of bleomycin on reproductive cells.
  • To explore factors contributing to differential susceptibility to bleomycin.

Main Methods:

  • Mice were treated with varying doses of bleomycin.
  • Dominant lethal mutations and cytotoxic effects were assessed in reproductive cells of both sexes.
  • Dose-response relationships were analyzed.

Main Results:

  • Bleomycin induced no dominant lethal or cytotoxic effects in male mice, even at maximum tolerated doses.
  • In female mice, a lower dose of bleomycin induced significant dominant lethal mutations.
  • Bleomycin also caused oocyte death in specific follicular development stages in females.

Conclusions:

  • Bleomycin demonstrates female-specific induction of dominant lethal mutations in mice.
  • This finding suggests potential gender-specific genetic risks associated with bleomycin chemotherapy.
  • Further research is needed to elucidate the mechanisms behind this differential susceptibility.